[1]孙爱学① 钱国军＊ 盛月红 屈秀娟 胡鹏 张少君.伴肾功能不全的肝脏恶性肿瘤行消融治疗的临床观察[J].中国微创外科杂志,2013,13(7):653-655.
　Sun Aixue,Qian Guojun*,Sheng Yuehong*,et al.Clinical Observation of Ablation Therapy in the Treatment of Patients with Hepatic Malignant Tumors and Renal Insufficiency[J].Chinese Journal of Minimally Invasive Surgery,2013,13(7):653-655.
点击复制

伴肾功能不全的肝脏恶性肿瘤行消融治疗的临床观察()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
13
期数:
2013年7期
页码:
653-655
栏目:
短篇论著
出版日期:
2013-07-20

文章信息/Info

Title:
Clinical Observation of Ablation Therapy in the Treatment of Patients with Hepatic Malignant Tumors and Renal Insufficiency
作者:
孙爱学① 钱国军＊ 盛月红 屈秀娟 胡鹏 张少君
第二军医大学附属东方肝胆外科医院微创一科，上海200438
Author(s):
Sun Aixue;  Qian Guojun*;  Sheng Yuehong*;  et al.
*Department of Minimal Invasive Therapy, Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China
关键词:
肾功能不全; 肝脏恶性肿瘤; 消融治疗
Keywords:
Renal insufficient; Hepatic malignant tumors; Ablation therapy
分类号:
R735.7
文献标志码:
A
摘要:
目的探讨伴肾功能不全的肝癌行消融治疗的安全性与有效性，以及术后肾功能恶化的发生率。方法2004年2月~2012年9月，16例伴肾功能不全的肝脏恶性肿瘤行24次经皮超声引导肝穿刺微波或射频消融治疗。肾功能分期：代偿期11例，失代偿期5例。10例消融1次，5例2次，1例4次。观察消融术后并发症、疗效以及肾功能变化情况。结果16例初次消融术后围手术期肾功能衰竭发生率6.2%（1/16）；初次消融完全消融率87.5%（14/16）。初次消融至末次消融后，肾功能恶化（肾功能分期由某一期进展为更高级别一期）发生率18.8%(3/16)。结论肾功能不全的肝脏恶性肿瘤行消融治疗有效，但可能增加术后肾功能衰竭的发生率。
Abstract:
ObjectiveTo explore the safety and efficacy of percutaneous ablation for treating patients with hepatic malignant tumors accompanied by renal insufficiency, and the incidence of renal function deterioration after the treatment.MethodsBetween February 2004 and September 2012, 16 patients with hepatic malignant tumors accompanied by renal insufficiency underwent a total of 24 percutaneous ultrasound guided microwave or radiofrequency ablation treatments. Different stages of renal function include 11 cases of renal compensatory and 5 cases of renal decompensation. 10 cases received 1 treatment of ablation therapy, 5 cases were treated 2 times, and 1 case was treated 4 times. After the treatment, the patients were kept under observation for complications, the efficacy of the first ablation therapy and the changes of renal function. ResultsDuring the perioperative period of first ablation therapy, the incidence of renal failure was 6.2% (1/16). The rate of complete ablation after receiving first ablation therapy was 87.5% (14/16). After the 24 ablation treatments, the rate of renal function deterioration was 18.8% (3/16) (deterioration means the renal function changed from one stage to more advanced stage). ConclusionAblation therapy for treating patients with hepatic malignant tumors and renal insufficiency is effective, while the incidence of renal failure may increase due to renal insufficiency.

参考文献/References:

[1]Ferlay J,Shin HR,Bray F,et al.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.Int J Cancer,2010,127(12):2893-2917.
[2]Llovet JM,Brú C,Bruix J.Prognosis of hepatocellular carcinoma:the BCLC staging classification.Semin Liver Dis,1999,19(3):329-338.
[3]Sato S,Shiratori Y,ImamuraM,et al.Power Doppler signals after percutaneous ethanol injection therapy for hepatocellular carcinoma predict local recurrence of tumors: a prospective study using 199 consecutive patients.J Hepatol,2001,35(2):225-234.
[4]陈再英．钟南山，主编．内科学．第7版．北京：人民卫生出版社，2009.549-550.
[5]Goldberg SN,Charboneau JW, Dodd GD 3rd Grassi CJ,Cardella J.F,et al.Imageguided tumor ablation:proposal for standardization of terms and reporting criteria. Radiology,2003,228(2):335-345.
[6]Ong SL,Gravante G,Metcalfe MS,et al.Efficacy and safety of microwave ablation for primary and secondary liver malignancies:a systematic review.Eur J Gastroenterol Hepatol,2009,21(6):599-605.
[7]中国抗癌协会肝癌专业委员会，中国抗癌协会临床肿瘤学协作专业委员会，中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治的专家共识.肿瘤,2009,29（4）：295-304.
[8]Livraghi T,Meloni F,Solbiati L,et al.Complications of microwave ablation for liver tumors:results of a multicenter study.Cardiovasc Intervent Radiol,2012,35(4):868-874.
[9]Cho HS,Seo JW,Kang Y,et al.Incidence and risk factors for radiocontrastinduced nephropathy in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization.Clin Exp Nephrol,2011,15(5):714-719.
[10]刘树佳，王在国，袁湘瑜,等.肝癌射频消融联合无水酒精注射治疗后急性肾功能衰竭的防治.四川肿瘤防治，2005，18（4）：229-231.
[11]Huo TI,Hsu CY,Huang YH,et al.Diabetesmellitus as an independent prognostic predictor and its associationwith renal dysfunction in patientswith hepatocellular carcinoma.Liver Int,2009,143(2):198-207.
[12]Lehner SG,Gould JE,Saad EA,et al.Tumor lysis syndrome after radiofrequency ablation of hepatocellular carcinoma. AJR Am J Roentgenol,2005,185(5):1307-1309.
[13]Kondo Y,Yoshida H,Tomizawa Y,et al.Percutaneous radiofrequency ablation of hepatocellular carcinoma in 14 patients undergoing regularhemodialysis for endstage renal disease.AJR Am J Roentgenol,2009,193(4):964-969.

备注/Memo

备注/Memo:
＊通讯作者,Email:qgjs@sina.com①苏州大学研究生部
更新日期/Last Update: 2014-10-14